ReShape Lifesciences Inc. (RSLS)
ReShape Lifesciences Statistics
Share Statistics
ReShape Lifesciences has 3.31M shares outstanding. The number of shares has increased by -96.96% in one year.
| Shares Outstanding | 3.31M |
| Shares Change (YoY) | -96.96% |
| Shares Change (QoQ) | 40.66% |
| Owned by Institutions (%) | 0.04% |
| Shares Floating | 598.88K |
| Failed to Deliver (FTD) Shares | 45 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 25.01K, so 3.43% of the outstanding shares have been sold short.
| Short Interest | 25.01K |
| Short % of Shares Out | 3.43% |
| Short % of Float | 3.62% |
| Short Ratio (days to cover) | 0.22 |
Valuation Ratios
The PE ratio is -0.13 and the forward PE ratio is -10.81. ReShape Lifesciences's PEG ratio is 0.
| PE Ratio | -0.13 |
| Forward PE | -10.81 |
| PS Ratio | 0.17 |
| Forward PS | 0.2 |
| PB Ratio | 0.22 |
| P/FCF Ratio | -0.09 |
| PEG Ratio | 0 |
Enterprise Valuation
ReShape Lifesciences Inc. has an Enterprise Value (EV) of -2.81M.
| EV / Earnings | 0.25 |
| EV / Sales | -0.32 |
| EV / EBITDA | 0.19 |
| EV / EBIT | 0.19 |
| EV / FCF | 0.17 |
Financial Position
The company has a current ratio of 2.73, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.73 |
| Quick Ratio | 1.74 |
| Debt / Equity | 0.04 |
| Total Debt / Capitalization | 3.78 |
| Cash Flow / Debt | -64.73 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.71% and return on capital (ROIC) is -212.36%.
| Return on Equity (ROE) | -1.71% |
| Return on Assets (ROA) | -1.07% |
| Return on Capital (ROIC) | -212.36% |
| Revenue Per Employee | $299,241.38 |
| Profits Per Employee | $-392,655.17 |
| Employee Count | 29 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 0.84 |
Taxes
| Income Tax | 52K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -93.76% in the last 52 weeks. The beta is 1.58, so ReShape Lifesciences's price volatility has been higher than the market average.
| Beta | 1.58 |
| 52-Week Price Change | -93.76% |
| 50-Day Moving Average | 2.44 |
| 200-Day Moving Average | 6.74 |
| Relative Strength Index (RSI) | 23.34 |
| Average Volume (20 Days) | 1.17M |
Income Statement
In the last 12 months, ReShape Lifesciences had revenue of 8.68M and earned -11.39M in profits. Earnings per share was -110.88.
| Revenue | 8.68M |
| Gross Profit | 5.55M |
| Operating Income | -14.64M |
| Net Income | -11.39M |
| EBITDA | -14.48M |
| EBIT | -14.64M |
| Earnings Per Share (EPS) | -110.88 |
Balance Sheet
The company has 4.46M in cash and 262K in debt, giving a net cash position of 4.2M.
| Cash & Cash Equivalents | 4.46M |
| Total Debt | 262K |
| Net Cash | 4.2M |
| Retained Earnings | -635.57M |
| Total Assets | 5.62M |
| Working Capital | 1.31M |
Cash Flow
In the last 12 months, operating cash flow was -16.96M and capital expenditures -43K, giving a free cash flow of -17M.
| Operating Cash Flow | -16.96M |
| Capital Expenditures | -43K |
| Free Cash Flow | -17M |
| FCF Per Share | -165.56 |
Margins
Gross margin is 63.93%, with operating and profit margins of -168.69% and -131.22%.
| Gross Margin | 63.93% |
| Operating Margin | -168.69% |
| Pretax Margin | -130.62% |
| Profit Margin | -131.22% |
| EBITDA Margin | -166.92% |
| EBIT Margin | -168.69% |
| FCF Margin | -195.93% |
Dividends & Yields
RSLS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -16549.25% |
| FCF Yield | -773.61% |
Analyst Forecast
Currently there are no analyst rating for RSLS.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Sep 23, 2024. It was a backward split with a ratio of 1:58.
| Last Split Date | Sep 23, 2024 |
| Split Type | backward |
| Split Ratio | 1:58 |
Scores
| Altman Z-Score | -162.39 |
| Piotroski F-Score | 3 |